Catalysts / PHAR
Upcoming FDA decisions and readouts we track for Pharming Group, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Pharming Group (PHAR, listed on Nasdaq). It concerns Leniolisib (Joenja) lower doses (APDS in children aged 4+ weighing 13–27 kg).
First on the list: the PDUFA date for Leniolisib (Joenja) lower doses (APDS in children aged 4+ weighing 13–27 kg), dated 30 Jan 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Pharming Group PHAR · Nasdaq | Leniolisib (Joenja) lower doses | APDS in children aged 4+ weighing 13–27 kg | 30 Jan 2027 in 114d |
PDUFA date | Verified | 6-K ↗ | No |
FreeBioList